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General Synthetic Procedures  
Unless otherwise noted, all reactions were performed under an argon atmosphere in oven-
dried glassware.  All purchased materials were used without further purification.  Thin layer 
chromatography (TLC) was carried out using Analtech Uniplate silica gel plates.  TLC plates 
were visualized using a combination of UV, p-anisaldehyde, ceric ammonium molybdate, 
ninhydrin, and potassium permanganate staining.  Flash chromatography was performed 
following the method of Still et al.,[1] using Sorbent Technologies Incorporated silica gel (32-63 
µM, 60 Å pore size).  NMR spectra were obtained on a Varian Inova 400 (400 MHz for 1H; 100 
MHz for 13C), or a Varian Mercury 300 (300 MHz for 1H; 75 MHz for 13C NMR) spectrometer.  
1H and 13C NMR chemical shifts are reported in parts per million (ppm) relative to TMS, with 
the residual solvent peak used as an internal reference.  Low-resolution electrospray ionization 
(ESI) mass spectra of small-molecules were recorded on a Water-Micromass LCT spectrometer.  
Reverse-phase HPLC purification was performed using a Beckman Coulter System Gold 126P 
equipped with System Gold 166P detector (λ= 220) and a C18 (21.2×150 mm) Beckman Coulter 
Ultraprep column using a gradient of 0.1% TFA in H2O and CH3CN as the mobile phase. 
 
	   2	  





The following is a slight modification of the literature protocol.  Sodium metal (120 mg, 5.21 
mmol) was added to ethanol (3 mL) at rt under argon.  After the sodium dissolved completely, 
diethyl malonate (850 mg, 5.45 mmol) was added to the sodium ethoxide solution followed by a 
slow addition of mesityl-d10 oxide (500mg, 4.62 mmol) at rt.  The solution was warmed to reflux 
(oil bath at 100 °C).  After 3 h reflux, the solution was cooled to rt and a solution of potassium 
hydroxide (625 mg, 11.14 mmol) in H2O (3 mL) was added.  The resulting solution was warmed 
to reflux (oil bath at 110 °C) for 6 h.  The solution was cooled to 0 °C and acidified with 6 N HCl 
to pH 3.  The resulting precipitate was filtered, washed with ice-cold water three times and 
purified by C18 reverse-phase HPLC (10 µm, 21.2×150 mm, Beckman Coulter) with a gradient 
of 0% B to 50 % B over 50 min (buffer A: 0.1% TFA in H2O; buffer B: 0.1% TFA in CH3CN) at 
a flow rate of 10 mL/min to provide the title compound (492 mg, 3.37 mmol) in 73 % yield.  1H 
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NMR (DMSO-d6, 400 MHz): δ 10.95 (s, 1H), 5.19 (s, 1H), 2.11(s, 4H). 13C NMR (DMSO-d6, 




2-Iodo-5,5-dimethyl-1,3-cyclohexanedione were synthesized according to established literature 
procedures.[2]   
 
1H NMR Time Course Experiment for Iododimedone Stability  
100 mM PBS (pH 6, 7, or 8) was prepared in D2O.  Iododimedone (4.0 mg, 15 µmol) was 
dissolved in PBS at pH 6, 7, or 8 in D2O with 10% DMSO-d6.  1H-NMR was obtained at 3, 10, 
30 min, 1, 2, 4, and 24 h.   
 
ESI-LC/MS Analysis of Lysine Incubated with Iododimedone 
To a solution of lysine (4.4 mg, 30 µmol) in 900 µL PBS (pH 7.4) was added a solution of 
iododimedone (2.7 mg, 10 µmol) in 100 µL DMSO at rt.  The resulting solutions were stirred for 
2 h at rt and then analyzed using a combination of TLC and ESI-LC/MS using a Shimadzu 
LCMS-2010 after separation on a Vydac Everest 2.1×250mm, 300Å, 5 µm reverse-phase C18 
monomeric column with a gradient of 5% to 65% B in 60 min (buffer A: 0.1% formic acid in 
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Cloning, Expression, and Purification of Recombinant Gpx3 
Recombinant Cys82Ser Gpx3 and Cys64Ser Cys82Ser Gpx3 proteins were expressed and 
purified as described previously.[3]  
 
Western Blot 
His-tagged C64S C82S Gpx3 (105.7 µM in 50 mM Tris-HCl pH 7.4) was reduced with DTT (10 
mM) for 30 min at 0 °C.  To remove small-molecules, reactions were passed successively 
through two Micro Bio-Spin P-30 columns (BioRad). C64S C82S Gpx3 (50 µM) was then 
untreated or treated with H2O2 (12.5, 25, 50, or 100 µM) for 10 min followed by dimedone (20 
mM) or iododimedone (20 mM).  The reactions were incubated for 1 h at rt and excess H2O2 
and/or iododimedone was quenched by the addition of DTT (100 mM).  The resulting samples 
were subjected to SDS-PAGE and Western blot analyses as reported previously.[4]  Equal protein 
loading was verified by staining with Ponceau S and α-His antibody (Pierce).   
 
ESI-LC/MS Analysis of Intact Gpx3 Labeled with Iododimedone 
C64S C82S Gpx3 and C82S Gpx3 (50 µM in 50 mM Tris-HCl pH 7.4) were reduced with DTT 
(10 mM) for 30 min at 0 °C and then treated with 50 mM iododimedone or DMSO for 2 h at rt.  
Small molecules were removed by passage through a Micro Bio-Spin P-30 column and analyzed 
using a Shimadzu LCMS-2010 after separation on a PLRP-S polymeric RP-HPLC column 
(50×2.1mm, 1000Å, 5 µm) using a gradient of 5% to 35% B in 30 min (buffer A: 0.1% formic 
acid in H2O; buffer B: 0.1% formic acid in CH3CN) at a flow rate of 0.2 mL/min.   
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Quantitative Analysis of Sulfenic-Acid Modification 
C64S C82S Gpx3 or C82S Gpx3 (100 µM in 50 mM Tris-HCl pH 7.4) were reduced as 
described above.  Gpx3 mutants (50 µM) were untreated or oxidized with H2O2 (12.5, 25, 50, or 
100 µM) in the presence of d6-dimedone (20 mM) for 1 h at rt.  Excess H2O2 was quenched by 
the addition of DTT (10 mM) for 10 min at 0 °C.  To remove small molecules, reactions were 
passed successively through two Micro Bio-Spin P-30 columns.  The resulting samples were 
treated with DTT (10 mM) for 30 min at 0 °C followed by iododimedone (50 mM).  After 2 h at 
rt, small molecules were removed and proteins were exchanged into 50 mM NH4CO3 (pH 8) 
using a Micro Bio-Spin P-30 column.  The resulting samples were treated with DTT (10 mM) for 
1 h at rt and digested with sequencing grade modified trypsin (Promega) for 24 h at 37 oC.  
Complete digestion was verified by SDS-PAGE.  Peptide digests were analyzed on a Shimadzu 
LCMS-2010 after separation on a Vydac Everest reverse-phase C18 monomeric column 
(2.1×250mm, 300Å, 5 µm) with a gradient of 5% to 65% B in 60 min (buffer A: 0.1% formic 
acid in H2O; buffer B: 0.1% formic acid in CH3CN) at a flow rate of 0.2 mL/min.  Digests of 
C82S Gpx3 were prepared as described above except that the protein was digested with 
sequencing grade chymotrypsin (Promega) for 24 h at 37 °C.  Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) from rabbit muscle was obtained as a powder (Sigma).  Digests of 
GAPDH were prepared as described above with the following modifications.  After reduction, 
GAPDH (25 µM) was untreated or oxidized with H2O2 (3.125, 6.25, 12.5, 25, or 50 µM) in the 
presence of d6-dimedone (10 mM) for 1 h at rt.  Excess H2O2 was quenched with DTT (10 mM) 
for 10 min at 0 °C.  Small molecules were removed and protein exchanged into 50 mM NH4CO3 
(pH 8) using a Micro Bio-Spin P-30 column.  Reactions were then treated with DTT (5 mM) for 
30 min at 0 °C followed by iododimedone (20 mM).  After 2 h at rt, excess iododimedone was 
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quenched with DTT (30 mM) for 1 h at rt and the protein was digested with Sequencing Grade 
Modified Trypsin (Promega) for 24 h at 37 °C. 
 
Figure Legends 
Figure S1. Possible mechanisms for S-alkylation by iododimedone.  (A) Nucleophilic attack of 
the thiolate at the secondary iodine atom in iododimedone furnishes a sulfenyl halide 
intermediate, which reacts with the dimedone nucleophile to give the S-alkylation product.  
Should the reaction mechanism in Figure S1A be operational, the resulting sulfenyl iodide also 
has the potential to react with protein thiols (or hydrolyze to the sulfenic acid and then react with 
protein thiols).[5] If this mechanism is operational, the absence such side reactions in our 
reactions is most likely due to the fact that protein labeling was carried out at neutral pH 
(preventing hydrolysis) and in the presence of excess alkylating reagent.  (B) Nucleophilic 
substitution of the thiolate at the α-carbon in iododimedone to give the S-alkylation product. 
Figure S2. Iododimedone is stable under experimental conditions.  (A) The chemical shifts of 
iododimedone (15 µM) in PBS buffered solution (pH 7) with 90% D2O and 10% DMSO-d6 were 
monitored by 1H NMR at 3, 10, 30 min, 1, 2, 4, and 24 h.  (B) A plot of chemical shifts (ppm) of 
iododimedone plotted with respect to time (h). 
Figure S3. Iododimedone reacts with the low-molecular weight thiol GSH to afford the 
alkylation product.  Iododimedone (15 µM) in DMSO (100 µL) was reacted with GSH (10 µM) 
in PBS (pH 7) for 1 h at rt.  The reaction was analyzed by LC-MS.  (A) Chemical structure of 
dimedone-labeled GSH (GS-Dimedone).  (B) Dimedone-labeled GSH was resolved by reverse-
phase C18 column chromatography.  (C) MS analysis confirmed the covalent dimedone adduct 
of GSH (446 Da). 
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Figure S4. Iododimedone does not cross-react with lysine.  (A) Iododimedone (10 µmol) in 
DMSO (100 µL) was added to a solution of lysine (30 µmol) in 900 µL PBS (pH 7.4) for 2 h at 
rt.  The reaction was resolved by reverse-phase C18 column chromatography to yield two peaks.  
(B) Peak A had a mass of 174 Da, corresponding to unmodified lysine.  (C) Peak B had a mass 
of 267 Da, consistent with the mass of unreacted iododimedone. 
Figure S5. ESI-LC/MS shows quantitative labeling of Gpx3 residues Cys36 and Cys63 by 
iododimedone.  C82S Gpx3 (50 µM) was reduced with DTT (10 mM) for 30 min at 0 °C and 
then treated with iododimedone (50 mM) or DMSO for 2 hours at rt.  The resulting protein was 
then analyzed by ESI-LC/MS.  (A) The observed molecular weight of C82S Gpx3 treated with 
DMSO only was 22,754.8 Da corresponding to intact, unlabeled C82S Gpx3.  (B) The observed 
molecular weight of C82S Gpx3 treated with iododimedone (50 mM) was 23,034.1, 
corresponding to C82S Gpx3 with two dimedone adducts (∆m 279.4). 
Figure S6. High peroxide concentrations result in sulfinic acid modification of Gpx3.  (A) ESI-
MS analysis of C64S C82S Gpx3 sulfinic acid-modified peptide 36-43 (closed circle).  (B) Mock 
data illustrating how the fraction sulfenic acid can level off at an endpoint less than one.  High 
peroxide concentrations can decrease the apparent populations of both the RSH and RSOH forms 
of the protein by proceeding rapidly to the RSO2H state, which is not detectable by dimedone or 
iododimedone probes.  (C) Graph of mock data presented in (B). 
Figure S7.  Quantifying peroxide-dependent sulfenic acid modification of C82S Gpx3.  The 
molecular ions corresponding to m/z of 541 and 544 are consistent with the masses of peptide 36-
43 tagged with ‘light’ dimedone and sulfenic acid-modified peptide 36-43 tagged by ‘heavy’ 
dimedone, respectively.  (B) To monitor the peptide fragment of Gpx3 containing Cys64, the 
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protein was digested with sequencing grade chymotrypsin.  The molecular ion corresponding to 
m/z of 639 is consistent with the mass of peptide 58-67 tagged with ‘light’ dimedone.  No ‘heavy’ 
dimedone-tagged peptide was observed.  (C) Fraction sulfenic acid at Cys36 (circles) and Cys64 
(diamonds) plotted as a function of H2O2 concentration.  Error bars represent ± s.d. calculated 
from duplicate experiments. 
Figure S8. Quantifying peroxide-dependent sulfenic acid modification of GAPDH. The 
molecular ion corresponding to m/z of 820 is consistent with the mass of peptide 232-245 tagged 
with ‘light’ dimedone; ‘heavy’ dimedone-tagged peptide was not observed.  
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